logo-loader

EARLY MOVERS - Loxo Oncology shares skyrocket on news of Eli Lilly acquisition; DXC Technology to buy Luxoft Holding

Also in the frame in pre-market is electric car titan Tesla and media group CBS Corp

1546866411_bethesda-naval-medical-center-80380_1280.jpg
Another cancer-related deal was in the news after the Bristol-Myers, Celgene announcement last week

In pre-market Monday, drugs giant Eli Lilly And Co (NYSE:LLY) was in focus, with shares shedding almost 3% before the New York bell to $114.66.

It comes after the group revealed it would buy Loxo Oncology Inc (NASDAQ:LOXO) for about $8 billion in cash, giving it a portfolio of targeted medicines to treat cancers.

Loxo shares skyrocketed nearly 65% on the news to $231.15.

The offer price of $235 per share in cash represents a premium of about 68% to Loxo's Friday close.

Last year, regulators approved Loxo's first commercial medicine called Vitrakvi, which had been shown to be effective against a wide variety of cancers.

Last week, Bristol-Myers Squibb Co (NYSE:BMY) announced it was buying Celgene Corp (NASDAQ:CELG) to expand its cancer and immunotherapy offering.

DXC Technology (NYSE:DXC) and Luxoft Holding Inc (NYSE:LXFT) Monday announced that DXC would acquire Luxoft, which is a global-scale digital innovator, headquartered in Switzerland.

DXC shares added 4.68% to $60 each, while Luxoft Holding Inc surged 45% before the New York bell.

All issued and outstanding Luxoft Class A and Class B ordinary shares will receive $59.00 per share in cash, representing a total equity value of around $2 billion.

To electric car giant Tesla (NASDAQ:TSLA) and shares in the firm are up 1.83% to $323.50 in pre-market. On Friday, shares closed nearly 6% higher.

Reportedly, Tesla has now officially begun building its Gigafactory in Shanghai Monday, with CEO Musk breaking ground at the new plant.

Also in the news, CBS News said Susan Zirinsky, a senior executive producer, will become president from March this year as David Rhodes is stepping down.

Rhodes will remain at CBS until the beginning of March, when he will become a senior adviser to parent company CBS Corp (NYSE:CBS). CBS Corp shares closed 2.25% higher on Friday at $47.17.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

2 days, 4 hours ago

2 min read